Benzo(a)pyrene diol epoxide-induced chromosome 9p21 aberrations are associated with increased risk of bladder cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 9, 2008, Pages 2445-2450

  Gu, Jian ^a   Horikawa, Yohei ^a,b   Chen, Meng ^a   Dinney, Colin P ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZO[A]PYRENE; DIHYDROXYBENZO[A]PYRENE OXIDE;

ADULT; ARTICLE; BLADDER CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CELL CULTURE; CENTROMERE; CHROMOSOME 9; CHROMOSOME 9P; CHROMOSOME ABERRATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; ETHNICITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SMOKING;

7,8-DIHYDRO-7,8-DIHYDROXYBENZO(A)PYRENE 9,10-OXIDE; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MUTAGENS; RISK; URINARY BLADDER NEOPLASMS;

EID: 53349101226     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2890     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Murray T, XU J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Vineis P, Alavanja M, Buffler P, et al. Tobacco and Cancer: Recent Epidemiological Evidence. J Natl Cancer Inst 2004;96:99-106.
3. Sugano K, Kakizoe T. Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging. Nat Clin Pract Urol 2006;41:642-52.
4. Stadler WM, Steinberg G, Yang X, Hagos F, Turner C, Olopade OI. Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization. Clin Cancer Res 2001;7:1676-82.
5. Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, Knuechel R. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 1999;154:721-7.
6. van Oers JM, Adam C, Denzinger S, et al. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasia of the bladder. Int J Cancer 2006;119:1212-5.
7. Carins P, Tokino K, Eby Y, Sidransky D. Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res 1994;54:1422-4.
8. Carins P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A. Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nature Genet 1995;11:210-2.
9. Mao L, Lee JS, Kurie JM, et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 1997;89:857-62.
10. Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997;89:1366-72.
11. Wu X, Gu J, Spitz MR. Mutagen sensitivity: a genetic predisposing factor for cancer. Cancer Res 2007;67:3493-5.
12. Wu X, Zhao Y, Honn SE, Tomlinson GE, Minnua JD, Hong WK. Benzo(a)pyrene diol epoxide-induced 3p21.3 aberrations and genetic predisposition to lung cancer. Cancer Res 1998;58:1605-8.
13. Wu X, Lippman SM, Lee JJ, Zhu Y, Wei QV, Thomas M. Chromosome instability in lymphocytes: A potential indicator of predisposition to oral premalignant lesions. Cancer Res 2002;62:2813-8.
14. Hazra A, Grossman HB, Zhu Y, Luo S, Spitz MR, Wu X. Benzo(a)pyrene diol epoxide-induced 9p21 aberrations associated with genetic predisposition to bladder cancer. Genes Chromosomes Cancer 2004;41:330-8.
15. Hsu TC, Johnston DA, Cherry LM, et al. Sensitivity to genotoxic effects of bleomycin in humans: possible relationship to environmental carcinogenesis. Int J Cancer 1989;43:403-9.
16. Yunis JJ, Ramsay N. Retinoblastoma and subband deletion of chromosome 13. Am J Dis Child 1978;132:161-3.
17. Yunis JJ, Ramsay N. Familial occurrence of the aniridia Wilm's tumor syndrome with deletion 11p13-14.1. J Pediatr 1980;96:1027-30.
18. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 1987;235:1394-9.
19. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990;60:509-20.
20. Sundareshan TS, Augustus M. Expression of common fragile sites in lymphocytes of Wilms tumor in patients, their parents, and siblings: a study of ten families. Cancer Genet Cytogenet 1995;84:51-5.
21. Egeli U, Karadag MK, Tunca B, Ozyardimci N. The expression of common fragile sites and genetic predisposition to squamous cell lung cancers. Cancer Genet Cytogenet 1987;95:153-8.
22. Yunis JJ, Soreng AL, Bowe AE. Fragile sites are targets of diverse mutagens and carcinogens. Oncogene 1987;1:59-69.
23. Yunis JJ. Multiple recurrent genomic rearrangements and fragile sites in human cancer. Somat Cell Mol Genet 1987;13:397-403.
24. Udumudi A, Jaiswal M, Rajeswari N, et al. Risk assessment in cervical dysplasia patients by single cell gel electrophoresis assay: a study of DNA damage and repair. Mutat Res 1998;412:195-205.
25. Pathak S, Hopwood VL, Hughes JI, Jackson GL. Identification of colon cancer-predisposed individuals: a cytogenetic analysis. Am J Gastroenterol 1991;86:679-84.
26. Bonassi S, Abbondandolo A, Camurri L, et al. Are chromosome aberrations in circulating lymphocytes predictive of future cancer onset in humans? Preliminary results of an Italian cohort study. Cancer Genet Cytogenet 1995;79:133-5.
27. Hagmar L, Brogger A, Hansteen I, et al. Cancer risk in humans predicted by increased levels of chromosome aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer Res 1994;54:2919-22.
28. Bonassi S, Hagmar L, Stromberg U, et al. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. European Study Group on Cytogenetic Biomarkers and Health. Cancer Res 2000;60:1619-25.
29. Bonassi S, Znaor A, Norppa H, Hagmar L. Chromosomal aberrations and risk of cancer in humans: an epidemiologic perspective. Cytogenet Genome Res 2004;104:376-82.
30. Wu X, Gu J, Amos CI, Jiang H, Hong WK, Spitz MR. A parallel study of in vitro sensitivity to benzo[a]pyrene diol epoxide and bleomycin in lung carcinoma cases and controls. Cancer 1998;83:1118-27.
31. Schabath MB, Spitz MR, Grossman HB, et al. Genetic instability in bladder cancer assessed by the comet assay. J Natl Cancer Inst 2003;95:540-7.
32. Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000;92:874-97.
33. Shao L, Lerner SL, Bondaruk J, et al. Specific chromosome aberrations in peripheral blood lymphocytes are associated with risk of bladder cancer. Genes Chromosomes Cancer 2004;41:379-89.
34. Kasuba V, Sentija K, Garaj-Vrhovac V, Fuciæ A. Chromosome aberrations in peripheral blood lymphocytes from control individuals. Mutat Res 1995;346:187-93.
35. Galloway SM, Berry PK, Nichols WW, et al. Chromosome aberrations in individuals occupationally exposed to ethylene oxide, and in a large control population. Mutat Res 1986;170:55-74.
36. Maffei F, Angelini S, Forti GC, et al. Spectrum of chromosomal aberrations in peripheral lymphocytes of hospital workers occupationally exposed to low doses of ionizing radiation. Mutat Res 2004;547:91-9.
37. Milillo CP, Gemignani F, Sbrana I, Carrozzi L, Viegi G, Barale R. Chromosome aberrations in humans in relation to site of residence. Mutat Res 1996;360:173-9.
38. Cloos J, Steen I, Joenje H, et al. Association between bleomycin genotoxicity and non-constitutional risk factors for head and neck cancer. Cancer Lett 1993;74:161-5.
39. King TM, Trizna Z, Wu X, et al. A clinical trial to evaluate the effect of vitamin C supplementation on in vitro mutagen sensitivity. The University of Texas M. D. Anderson Clinical Community Oncology Program Network. Cancer Epidemiol Biomarkers Prev 1997;6:537-42.
40. Shigyo M, Sugano K, Tobisu K, Tsukamoto T, Sekiya T, Kakizoe T. Molecular follow-up of newly diagnosed bladder cancer using urine samples. J Urol 2000;166:1280-5.